Thyroid Cancer Diagnostics Market Report 2025

The thyroid cancer diagnostics market size has grown strongly in recent years. It will grow from $2.99 billion in 2024 to $3.16 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to increasing prevalence of thyroid cancer, aging population, rising awareness and early detection, government initiatives and funding, improved healthcare infrastructure.

The thyroid cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.01 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to growing demand for companion diagnostics, increasing patient preference for personalized medicine, economic growth and healthcare spending, physician education and training, regulatory approvals and clearances. Major trends in the forecast period include liquid biopsies, globalization of diagnostic technologies, technological advancements, research and development, integration of artificial intelligence, collaborations and partnerships.

The anticipated increase in thyroid cancer cases is set to drive the expansion of the thyroid cancer diagnostic market. Thyroid cancer, a condition affecting the thyroid gland, necessitates early detection for improved treatment outcomes. Diagnostic tools play a crucial role in identifying thyroid cancer at an early stage, meeting the rising demand for effective diagnostic solutions. According to a September 2023 report by the American Cancer Society, an estimated 43,720 new cases of thyroid cancer are expected in 2023, emphasizing the need for diagnostic advancements. The report further projects approximately 2,120 deaths from thyroid cancer in the same year. Consequently, the escalating prevalence of thyroid cancer is a significant driver propelling the thyroid cancer diagnostic market.

The growth of healthcare spending is poised to further boost the thyroid cancer diagnostics market. Healthcare spending, encompassing financial resources allocated to healthcare provision, is a key factor influencing diagnostic market dynamics. The increased investment in healthcare contributes to the research, development, and implementation of advanced diagnostic technologies. This investment enhances accessibility and affordability of innovative tools, fostering early detection and improved management of thyroid cancer. As indicated in the 2021-2030 National Health Expenditure report by the Centers for Medicare & Medicaid Services, the projected annual growth in national health spending is expected to reach 5.1% between 2021 and 2030, totaling nearly $6.8 trillion. With specific focus on Medicare and Medicaid, spending is anticipated to rise at rates of 7.2% and 5.6% annually, respectively. Thus, increased healthcare spending is a key driver fueling the growth of the thyroid cancer diagnostics market.

Major companies in the thyroid cancer diagnostic market are focusing on developing innovative solutions, such as RNA sequencing tests, to improve the accuracy of cancer fusion detection across various solid tumors, including thyroid cancer. RNA sequencing (RNA-Seq) is a high-throughput technique that allows for the analysis of RNA quantity and sequence in a sample, offering insights into gene expression and the overall transcriptome. For example, in March 2024, Foundation Medicine, Inc., a US-based biotechnology company, announced the U.S. launch of FoundationOne RNA, a tissue-based RNA sequencing test designed to detect cancer-related gene fusions across 318 genes. This test provides fusion reporting for all solid tumors and may be especially useful for identifying fusions in cancers such as non-small cell lung cancer (NSCLC), sarcoma, pancreatic cancer, thyroid cancer, cholangiocarcinoma, and bladder cancer.

Major companies in the thyroid cancer diagnostic market are also focusing on the development of innovative products, such as rearranged during transfection (RET) inhibitors. RET inhibitors specifically target and inhibit the activity of the RET protein. CStone Pharmaceuticals gained approval for GAVRETO (pralsetinib) in March 2022. GAVRETO is a selective RET inhibitor sanctioned in China for managing RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer (TC). This oral targeted therapy addresses the needs of patients with various forms of thyroid cancer, contributing to enhanced diagnostic and treatment options.

In September 2024, The World Tumor Registry (WTR), a US-based non-profit organization focused on the collection and analysis of tumor data, partnered with PathPresenter. This collaboration supports WTR's mission to develop an accessible educational resource for cancer care and research organizations globally, offering a secure and scalable solution to improve cancer diagnostics and education. PathPresenter is a US-based multi-tenant enterprise pathology workflow software platform.

Major companies operating in the thyroid cancer diagnostics market include Pfizer Inc., General Electric, F. Hoffmann-La Roche AG, Bayer AG, Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Toshiba Corporation, Merck KGaA, Siemens Healthcare GmbH, FUJIFILM Holdings Corporation, Koninklijke Philips N.V., AstraZeneca plc, Agilent Technologies Inc., Hologic Inc., Genzyme Corporation, Illumina Inc., BioMérieux SA, Bio-Rad Laboratories Inc., Quest Diagnostics Inc., Qiagen N.V., Cepheid, Veracyte Inc., DiaSorin S.p.A., Myriad Genetics Inc.

North America was the largest region in the thyroid cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thyroid cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the thyroid cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Thyroid cancer diagnostics involves the use of techniques to examine a lump or nodule suspected of being thyroid cancer, aiding in the identification and diagnosis of thyroid cancer. Thyroid cancer is a type of cancer that originates in the thyroid gland when cells undergo uncontrolled growth.

The primary techniques used in thyroid cancer diagnostics include imaging tests, blood tests, biopsies, and other diagnostic procedures. Imaging involves creating visual representations of phenomena such as temperature, sound waves, chemicals, or electrical activity. In the context of thyroid cancer diagnostics, imaging tests are utilized to generate images of the thyroid gland. Different types of thyroid cancer include papillary carcinoma, follicular carcinoma, and others. These diagnostic techniques are employed by various end-users, including hospital laboratories, cancer diagnostic centers, research institutes, and others.

The thyroid cancer diagnostics market research report is one of a series of new reports that provides thyroid cancer diagnostics market statistics, including thyroid cancer diagnostics industry global market size, regional shares, competitors with a thyroid cancer diagnostics market share, detailed thyroid cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the thyroid cancer diagnostics industry. This thyroid cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The thyroid cancer diagnostics market includes revenues earned by entities by providing diagnostic tools related detection and diagnosis of thyroid cancer, radioactive tracer, biopsy, blood tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.